Unnamed: 0,title,date,stock,sentiment
1082445.0,Regulus Therapeutics Q1 EPS $(0.250) Up From $(0.310) YoY,2020-05-14 16:12:00-04:00,RGLS,neutral
1082446.0,"Shares of several companies in the broader healthcare sector are trading lower amid market weakness despite recent strength from many names in the space. Equities are down for the session following cautious comments from US Fed Chair Powell, which forecast uncertainty and downside risk. Some regions of the US have extended lockdown restrictions, including Washington D.C.  and Los Angeles County.",2020-05-13 12:49:00-04:00,RGLS,negative
1082447.0,"HC Wainwright & Co. Reiterates Buy on Regulus Therapeutics, Lowers Price Target to $1.5",2020-05-04 07:21:00-04:00,RGLS,negative
1082448.0,Regulus Therapeutics Q4 EPS $(0.23) Up From $(0.98) YoY,2020-03-12 16:37:00-04:00,RGLS,neutral
1082449.0,Regulus Therapeutics Reinitiates Multiple Ascending Dose Study Of RGLS4326 For The Treatment Of ADPKD,2020-02-13 16:34:00-05:00,RGLS,neutral
1082450.0,Regulus Therapeutics Announces FDA Removal of Partial Clinical Hold for Multiple Ascending Dose Study of RGLS4326,2019-12-16 08:02:00-05:00,RGLS,neutral
1082451.0,"Regulus Therapeutics Q3 EPS $(0.26) Up From $(1.18) YoY, Sales $18K, Same YoY",2019-11-12 16:19:00-05:00,RGLS,neutral
1082452.0,Regulus Therapeutics shares are trading higher after H.C. Wainwright initiated coverage on the stock with a Buy rating and a price target of $2 per share.,2019-09-06 11:33:00-04:00,RGLS,positive
1082453.0,"H.C. Wainwright Initiates Coverage On Regulus Therapeutics with Buy Rating, Announces $2 Price Target",2019-09-06 07:29:00-04:00,RGLS,neutral
1082454.0,Regulus Therapeutics shares are trading higher after the company reported Q2 EPS and sales are up from the same quarter last year.,2019-08-08 17:02:00-04:00,RGLS,positive
1082455.0,"Regulus Therapeutics Q2 EPS $(0.3) Up From $(1.59) YoY, Sales $18K, Same YoY",2019-08-08 16:59:00-04:00,RGLS,neutral
1082456.0,Regulus Therapeutics 13G By Altium Capital Mgmt. Shows New 9.99% Stake,2019-05-17 14:04:00-04:00,RGLS,neutral
1082457.0,"Regulus Therapeutics Q1 EPS $(0.31) Beats $(1.15) Estimate, Sales $6.778M Beat $10K Estimate",2019-05-09 17:00:00-04:00,RGLS,neutral
1082458.0,Regulus Therapeutics Announces Restructuring Of Term Loan,2019-05-06 09:16:00-04:00,RGLS,neutral
1082459.0,"Regulus Therapeutics Q4 EPS $(0.98) Misses $(0.92) Estimate, Sales $18K Miss $3.51M Estimate",2019-03-18 08:01:00-04:00,RGLS,negative
1082460.0,European Patent Office Documents Show Patent Related To Hepatitis C Awarded To Regulus Therapeutics,2019-01-09 15:17:00-05:00,RGLS,positive
1082461.0,Regulus Announces Nomination Of RGLS5579 For Treatment Of Glioblastoma Multiforme,2019-01-07 08:25:00-05:00,RGLS,neutral
1082462.0,"Regulus To Submit Comprehensive Data Package For RGLS4326 To FDA; Co. Previously Had Paused The Study Due To Unexpected Observations, No Adverse Or Other Significant Findings To Date",2019-01-04 16:07:00-05:00,RGLS,negative
1082463.0,Regulus Therapeutics Filing Shows Registration For $20M Common Stock Offering,2018-12-12 16:55:00-05:00,RGLS,neutral
1082464.0,Hearing Regulus Therapeutics Granted US Patent '484 For 'targeting microRNAs for metabolic disorders',2018-11-27 10:42:00-05:00,RGLS,positive
1082465.0,Regulus Therapeutics Presents New Data on its Novel Treatment for Glioblastoma Multiforme,2018-11-19 08:10:00-05:00,RGLS,positive
1082466.0,"Regulus Therapeutics 8-K Shows Co. Received Notice From Nasdaq The Co.'s Shareholders' Equity Reported On 1-Q For Qtr. Ended Sep. 30, 2018 Does Not Satisfy Continued Listing Requirement",2018-11-16 16:21:00-05:00,RGLS,negative
1082467.0,"Stocks Which Set New 52-Week Low Yesterday, Thurs., Nov. 8, 2018",2018-11-09 09:38:00-05:00,RGLS,negative
1082468.0,"Regulus Therapeutics Q3 EPS $(1.18) Beats $(1.25) Estimate, Sales $18K Beat $10K Estimate",2018-11-08 17:00:00-05:00,RGLS,neutral
1082469.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Wed., Nov. 7, 2018",2018-11-07 15:16:00-05:00,RGLS,positive
1082470.0,Wedbush On Regulus Therapeutics: Sees 'limited upside potential until safety concerns for RGLS4326 are mitigated by new 27-week mouse toxicity data in H1:19',2018-11-07 12:41:00-05:00,RGLS,positive
1082471.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Tues., Nov. 6, 2018",2018-11-06 14:55:00-05:00,RGLS,positive
1082472.0,Regulus Licenses miR-21 to Sanofi for $7M Upfront and Up to $40M in Development Milestones,2018-11-06 08:24:00-05:00,RGLS,neutral
1082473.0,"Stocks Which Set New 52-Week Low Yesterday, October 29th",2018-10-30 12:40:00-04:00,RGLS,negative
1082474.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Wed., Oct. 24, 2018",2018-10-24 09:40:00-04:00,RGLS,positive
1082475.0,Regulus Therapeutics shares are up 58.5% on heavy volume following a Monday press release announcing the company will present preclinical data on RGLS4326 for kidney disease at the American Society of Nephrology on Oct. 25.,2018-10-23 11:49:00-04:00,RGLS,positive
1082476.0,"Stocks Which Set New 52-Week Low Yesterday, October 22nd",2018-10-23 09:54:00-04:00,RGLS,negative
1082477.0,Regulus Therapeutics Shares Up 42% On Heavy Volume (~196K Shares) Following Co. Press Release Previewing Will Present Preclinical Data On RGLS4326 In Development For Autosomal Dominant Polycystic Kidney Disease At American Society of Nephrology Oct. 25,2018-10-22 17:04:00-04:00,RGLS,positive
1082478.0,Regulus Regains Compliance with NASDAQ Listing Requirements,2018-10-18 16:10:00-04:00,RGLS,neutral
1082479.0,"Stocks Which Set New 52-Week High Yesterday, October 4th",2018-10-05 09:20:00-04:00,RGLS,neutral
1082480.0,"Regulus Therapeutics Reports 1-For-12 Reverse Stock Split, Effective Oct. 4",2018-10-04 08:14:00-04:00,RGLS,positive
1082481.0,"Stocks Which Set New 52-Week Low Yesterday, August 14th",2018-08-15 12:34:00-04:00,RGLS,negative
1082482.0,Regulus Therapeutics Q2 EPS $(0.13) Beats $(0.16) Estimate,2018-08-09 16:44:00-04:00,RGLS,neutral
1082483.0,"Stocks Which Set New 52-Week Low Yesterday, August 8th",2018-08-09 11:10:00-04:00,RGLS,negative
1082484.0,"Stocks Which Set New 52-Week Low Yesterday, July 30th",2018-07-31 09:25:00-04:00,RGLS,negative
1082485.0,"Stocks Which Set New 52-Week Low Friday, July 27",2018-07-30 12:17:00-04:00,RGLS,negative
1082486.0,Wedbush Downgrades Regulus Therapeutics to Neutral,2018-07-10 08:06:00-04:00,RGLS,neutral
1082487.0,Regulus Therapeutics Shares Down 38.5% Premarket After Co. Late Thursday Announced Restructuring And 60% Workforce Reduction,2018-07-06 08:50:00-04:00,RGLS,positive
1082488.0,Regulus Therapeutics Shares To Resume Trade At 5:30 p.m. EDT,2018-07-05 17:05:00-04:00,RGLS,positive
1082489.0,UPDATE: Regulus Says Its Seeking To Partner For The Balance Of Its Preclinical Programs,2018-07-05 17:04:00-04:00,RGLS,neutral
1082490.0,UPDATE: Regulus Sees Filing Investigational New Drug Application For HBV Program In 2H'19,2018-07-05 17:04:00-04:00,RGLS,neutral
1082491.0,UPDATE: Regulus Says Co. Determined Advancing Preclinical Programs Targeting HBV Represented Most Attractive Opportunity In Its Pipeline For Investment,2018-07-05 17:03:00-04:00,RGLS,positive
1082492.0,"UPDATE: Regulus Offers Pipeline Update: Prelim. Results From First Patients Of RG-012 For Treatment Of Alport Syndrome: Kidney Tissue Concentrations Achieved Would Be Predictive Of Benefit Based On Animal Models, Modulation Of miR-21 Observed",2018-07-05 17:02:00-04:00,RGLS,positive
1082493.0,"Regulus Announces Strategic Update, Pauses Recruitment Activities For Its RG-012 Program In Alport Syndrome",2018-07-05 17:00:00-04:00,RGLS,neutral
1082494.0,Regulus Therapeutics Shares Halted News Pending,2018-07-05 16:57:00-04:00,RGLS,positive
1082495.0,"Regulus Therapeutics Q1 EPS $(0.15) Misses $(0.14) Estimate, Sales $18K, Same YoY",2018-05-10 16:14:00-04:00,RGLS,negative
1082496.0,Regulus Initiates Multiple Ascending Dose Study in Healthy Volunteers of RGLS4326 for the Treatment of ADPKD,2018-05-01 08:39:00-04:00,RGLS,positive
1082497.0,Regulus Therapeutics Reports Initiation Of Multiple Ascending Dose Study In Healthy Volunteers Of RGLS4326 For Treatment Of ADPKD,2018-05-01 08:38:00-04:00,RGLS,positive
1082498.0,"B. Riley Initiates Coverage On Regulus Therapeutics with Neutral Rating, Announces $1.00 Price Target",2018-03-28 08:01:00-04:00,RGLS,neutral
1082499.0,Regulus Therapeutics Reports Q4 EPS $(0.14) vs $(0.16) Est.,2018-03-07 16:10:00-05:00,RGLS,neutral
1082500.0,"Leerink Swann Initiates Coverage On Regulus Therapeutics with Outperform Rating, Announces $2.00 Price Target",2018-01-05 08:24:00-05:00,RGLS,neutral
1082501.0,Regulus Reports First-in-Human Dosing for Phase I Study of RGLS4326,2017-12-19 08:36:00-05:00,RGLS,neutral
1082502.0,"BMO Capital Maintains Market Perform on Regulus Therapeutics, Lowers Price Target to $1.00",2017-11-08 09:06:00-05:00,RGLS,negative
1082503.0,"Regulus Therapeutics Reports Q3 EPS $(0.18) vs $(0.16) Est., Sales $18K vs $860K Est.",2017-11-07 16:15:00-05:00,RGLS,neutral
1082504.0,Chardan Capital Downgrades Regulus Therapeutics to Neutral,2017-08-02 05:56:00-04:00,RGLS,neutral
1082505.0,"Regulus Reports Q2 EPS $(0.41) vs $(0.33) Est., Sales $18K vs $87K Est.",2017-08-01 16:16:00-04:00,RGLS,neutral
1082506.0,13G Filing From Broadfin Capital On Regulus Therapeutics Shows 5.65% Stake,2017-07-24 11:02:00-04:00,RGLS,neutral
1082507.0,"Regulus Announces Common Stock Offering, No Size Disclosed",2017-07-19 16:03:00-04:00,RGLS,negative
1082508.0,Regulus Names Dr. Mark Deeg Chief Medical Officer,2017-06-13 08:32:00-04:00,RGLS,neutral
1082509.0,Regulus Announces Pipeline Updates,2017-06-12 07:08:00-04:00,RGLS,neutral
1082510.0,Aptuit Reports Strategic Provider Agreement with Regulus Therapeutics For Range Of Discovery and Non-Clinical Services,2017-06-08 08:04:00-04:00,RGLS,positive
1082511.0,Regulus Shares to Resume Trade at 5 p.m. EDT,2017-05-04 16:56:00-04:00,RGLS,positive
1082512.0,"Regulus Says It Has Completed Dosing Of RG-012 In Phase 1 Study, Prelim Data Show RG-012 Well Tolerate",2017-05-04 16:32:00-04:00,RGLS,positive
1082513.0,"Regulus Reports Q1 EPS $(0.38) vs $(0.35) Est., Sales $18K vs $940K Est.",2017-05-04 16:31:00-04:00,RGLS,neutral
1082514.0,Regulus Shares Halted News Pending,2017-05-04 16:24:00-04:00,RGLS,positive
1082515.0,"Wedbush Reiterates Outperform On Regulus Therapeutics, Maintains $6 Price Target",2017-03-29 06:32:00-04:00,RGLS,neutral
1082516.0,"Cowen Annual Healthcare Conference Continues Today; Presenters Include Regulus, Eli Lilly, Oculus, DexCom, Illumina, Allergan, Kite Pharma, Pfizer, and bluebird bio",2017-03-07 08:59:00-05:00,RGLS,neutral
1082517.0,"Wedbush Reiterates Outperform On Regulus Therapeutics, Lowers Price Target To $6",2017-03-06 06:37:00-05:00,RGLS,negative
1082518.0,"Regulus Reports Q4 EPS $(1.55) May Not Compare To $(0.37) Est., Sales $18K May Not Compare To $920K Est.",2017-03-02 16:11:00-05:00,RGLS,neutral
1082519.0,"Leerink Partners Global Healthcare Conference Began Today; Presenters Include Mannkind, Universal Health Services, Celgene, Inogen, Endologix, Biogen, GW Pharma, Regulus, Fate Therapeutics, Puma Biotech, Allergan, Bristol Myers And Synergy Pharma",2017-02-15 10:29:00-05:00,RGLS,neutral
1082520.0,"Wedbush Maintains Outperform on Regulus Therapeutics, Lowers Target from $13 to $8.00",2017-01-30 12:20:00-05:00,RGLS,negative
1082521.0,Needham Downgrades Regulus Therapeutics To Hold,2017-01-30 07:42:00-05:00,RGLS,neutral
1082522.0,Wells Fargo Downgrades Regulus Therapeutics To Market Perform,2017-01-30 07:13:00-05:00,RGLS,positive
1082523.0,Regulus Therapeutics Shares Halted News Pending,2017-01-27 16:06:00-05:00,RGLS,positive
1082524.0,"Cantor Fitzgerald Initiates Coverage On Regulus Therapeutics at Overweight, Announces $11.00 Target",2016-12-16 09:01:00-05:00,RGLS,negative
1082525.0,BMO Capital Downgrades Regulus Therapeutics to Market Perform,2016-06-28 06:50:00-04:00,RGLS,neutral
1082526.0,"Chardan Capital Maintains Buy on Regulus Therapeutics, Raises PT from $15 to $20 in Mid-Day Note",2016-06-07 10:25:00-04:00,RGLS,neutral
1082527.0,"Chardan Capital Initiates Coverage on Regulus Therapeutics at Buy, Announces $15.00 PT",2016-04-13 05:22:00-04:00,RGLS,neutral
1082528.0,"BMO Capital Initiates Coverage on Regulus Therapeutics at Outperform, Announces $16.00 PT",2016-04-12 06:01:00-04:00,RGLS,neutral
1082529.0,Wells Fargo Initiates Coverage on Regulus Therapeutics at Outperform,2015-12-04 07:56:00-05:00,RGLS,positive
1082530.0,Guggenheim Securities Initiates Coverage on Regulus Therapeutics at Buy,2015-06-08 16:34:00-04:00,RGLS,positive
1082531.0,"Regulus Initiates Phase I Clinical Study of RG-012, a microRNA Therapeutic in Development for the Treatment of Alport Syndrome",2015-06-04 08:04:00-04:00,RGLS,neutral
1082532.0,Regulus Announces RG-101 Achieves Sustained HCV Viral Suppression with Favorable Safety and Tolerability,2015-04-25 11:56:00-04:00,RGLS,positive
1082533.0,"FBR Capital Initiates Coverage on Regulus Therapeutics at Outperform, Announces $30.00 PT",2015-04-21 06:20:00-04:00,RGLS,neutral
1082534.0,"Deutsche Bank Initiates Coverage on Regulus Therapeutics at Buy, Announces $30.00 PT",2014-11-24 06:08:00-05:00,RGLS,neutral
1082535.0,Regulus Therapeutics Reports Q3 EPS of $(0.26) vs $(0.23) Est; Revenue of $1.10M vs $2.59M Est,2014-11-05 16:14:00-05:00,RGLS,neutral
1082536.0,"Regulus Prices 5,294,118 Share Offering @$17.00/Share",2014-10-28 20:12:00-04:00,RGLS,positive
1082537.0,"A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment History",2014-10-22 07:34:00-04:00,RGLS,neutral
1082538.0,Regulus Enters New Collaboration Agreement with Biogen; Regulus to Receive $2M Upfront with Potential Future Milestone Payments,2014-08-05 08:12:00-04:00,RGLS,positive
1082539.0,Regulus Therapeutics Reports Q1 EPS of $(0.30) vs $(0.14) Est; Revenue of $1.60M vs $4.10M Est,2014-05-08 16:47:00-04:00,RGLS,neutral
1082540.0,Regulus Therapeutics Reports Q4 EPS of $(0.11) vs $(0.13) Est; Revenue of $5.45M vs $4.08M Est,2014-02-27 16:12:00-05:00,RGLS,neutral
1082541.0,Regulus Therapeutics Reports Q3 EPS of $(0.07) vs $(0.15) Est; Revenue of $6.12M vs $3.51M Est,2013-11-13 16:16:00-05:00,RGLS,neutral
1082542.0,"Lazard Capital Markets Maintains Buy on Regulus Therapeutics, Raises PT to $15.00",2013-08-14 09:01:00-04:00,RGLS,neutral
1082543.0,Regulus Therapeutics Reports Q4 EPS of $(0.22) vs $(0.07) Est; Revenue of $3.24M vs $3.30M Est,2013-02-20 16:46:00-05:00,RGLS,neutral
1082544.0,"Wedbush Securities Initiates Coverage Regulus Therapeutics With an Outperform Rating, Announces PT of $10.0",2012-11-29 07:56:00-05:00,RGLS,positive
